TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) just unveiled an announcement.
Shanghai Bio-Heart Biological Technology Co., Ltd. reported its interim results for the first half of 2025, marking a significant milestone with the global launch of its first commercial product, the Iberis® 2nd RDN system. The company achieved a revenue of RMB20.9 million, a notable increase from the previous year. The Iberis® RDN system received approval from the NMPA and completed its first commercial procedure in Europe, enhancing the company’s market presence. Additionally, the SAKURA-SCB trial in Japan successfully enrolled its first patient, indicating progress in their research initiatives.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-Heart Biological Technology Co., Ltd. operates in the biotechnology industry, focusing on the development and commercialization of medical devices for cardiovascular diseases. The company’s primary product is the Iberis® RDN system, which is used for the treatment of resistant hypertension and patients with drug intolerance.
Average Trading Volume: 1,727,139
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.5B
See more insights into 2185 stock on TipRanks’ Stock Analysis page.